Lynne Kelley is the Chief Medical Officer for Servier Pharmaceuticals, a global non-profit pharmaceutical company focused on developing and commercializing lifesaving oncology medications for both solid and liquid tumors. Her role is to lead the medical strategy and enable the business to achieve its goals for improved patient outcomes and sustainable growth.
Lynne is a general and vascular surgeon and member of the American College of Surgeons. She brings over 15 years of industry experience across a wide array of therapeutic areas including oncology, rare and orphan diseases, devices and diagnostics. She has led global teams of medical professionals spearheading innovation, due diligence, clinical trials (ranging from novel drug products, biologics, medical devices and drug-device combinations including being a principal investigator), safety evaluations, product development and key opinion leader management. She has served as an executive of the medical function at multinational companies such as Becton Dickinson and Kimberly Clark and Chief Medical Officer of Senseonics, Histogenics and most recently X4 Pharmaceuticals.
Lynne received her Doctor of Medicine from Dartmouth Medical School, completed her surgical residency at Dartmouth Hitchcock and her vascular surgery fellowship at Massachusetts General Hospital and an additional endovascular surgery fellowship at Hospital Henri Mondor in Paris France. She practiced at Yale University including teaching residents and fellows. Lynne is on the board of advisors for The Center of Health Equity at Dartmouth Medical School and is on the board of directors for Equalize Heath (formerly D-rev).